The worldwide emergence and dissemination of Gram-negative bacteria expressing metallo-beta-lactamases (MBLs) menace the efficacy of all beta -lactam antibiotics, including carbapenems, a last line treatment usually restricted to severe pneumonia and urinary tract infections. Nonetheless, no MBL inhibitor is yet available in therapy. We previously identified a series of 1,2,4-triazole-3-thione derivatives acting as micromolar inhibitors of MBLs in vitro, but devoid of synergistic activity in microbiological assays. Here, via a multidisciplinary approach, including molecular modelling, synthesis, enzymology, microbiology, and X-ray crystallography, we optimized this series of compounds and identified low micromolar inhibitors active against clinically relevant MBLs (NDM-1- and VIM-type). The best inhibitors increased, to a certain extent, the susceptibility of NDM- 1- and VIM-4-producing clinical isolates to meropenem. X-ray structures of three selected inhibitors in complex with NDM-1 elucidated molecular recognition at the base of potency improvement, confirmed in silico predicted orientation, and will guide further development steps.

Structure-Based Optimization of 1,2,4-Triazole-3-Thione Derivatives: Improving Inhibition of NDM-/VIM-Type Metallo-beta -Lactamases and Synergistic Activity on Resistant Bacteria

Matteo Bersani
Co-first
;
Mariacristina Failla
Co-first
;
Eleonora Gianquinto;Laura Bertarini;Francesca Spyrakis;Loretta Lazzarato
;
2023-01-01

Abstract

The worldwide emergence and dissemination of Gram-negative bacteria expressing metallo-beta-lactamases (MBLs) menace the efficacy of all beta -lactam antibiotics, including carbapenems, a last line treatment usually restricted to severe pneumonia and urinary tract infections. Nonetheless, no MBL inhibitor is yet available in therapy. We previously identified a series of 1,2,4-triazole-3-thione derivatives acting as micromolar inhibitors of MBLs in vitro, but devoid of synergistic activity in microbiological assays. Here, via a multidisciplinary approach, including molecular modelling, synthesis, enzymology, microbiology, and X-ray crystallography, we optimized this series of compounds and identified low micromolar inhibitors active against clinically relevant MBLs (NDM-1- and VIM-type). The best inhibitors increased, to a certain extent, the susceptibility of NDM- 1- and VIM-4-producing clinical isolates to meropenem. X-ray structures of three selected inhibitors in complex with NDM-1 elucidated molecular recognition at the base of potency improvement, confirmed in silico predicted orientation, and will guide further development steps.
2023
16
ph16121682
1
22
https://www.mdpi.com/1424-8247/16/12/1682
1,2,4-triazole-3-thione, structure-based drug design, NDM-1, competitive inhibitors, resistance
Matteo Bersani; Mariacristina Failla; Filippo Vascon; Eleonora Gianquinto; Laura Bertarini; Massimo Baroni; Gabriele Cruciani; Federica Verdirosa; Fil...espandi
File in questo prodotto:
File Dimensione Formato  
2023_triazoli_pharmaceuticals.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 7.02 MB
Formato Adobe PDF
7.02 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1946126
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact